Loading
A phase 2 trial of Oregovomab, Paclitaxel / nab-paclitaxel, Carboplatin in ovarian cancer, run by CanariaBio Inc., active and no longer recruiting.
Oregovomab Plus Chemotherapy in Neo-adjuvant Setting in Newly Diagnosed Patients With Advanced Epithelial Ovarian Cancer is a phase 2 interventional study registered as NCT05605535 by CanariaBio Inc., with 88 participants planned, started 2023-02-07 and due to reach its primary completion in 2026-10-15. Interventions recorded: Oregovomab, Paclitaxel, Carboplatin, Placebo. Conditions listed: Ovarian Neoplasm Epithelial, Ovarian Cancer, Fallopian Tube Neoplasms, Peritoneal Carcinoma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares CanariaBio, Oregovomab, Paclitaxel / nab-paclitaxel, Platinum agents.
Shares CanariaBio, Oregovomab, Ovarian cancer.
Shares CanariaBio, Oregovomab, Ovarian cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/